Moreover, compared with other ligands, MICA/B and ULBP4 are moderately or highly expressed in more than 2/3 of HCC patients, which supported that the NKG2D ligands might serve as therapeutic targets. This evidence concerns the gene KLRK1 and hepatocellular carcinoma.